OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss

Purpose: Treatment with denosumab (DMAB) decreases bone resorption and fracture risk. Following discontinuation, bone resorption increases, bone mass is lost and fractures have been reported. The aim of the study was to investigate if an infusion of zoledronic acid (ZOL) can prevent increases in bon...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Endocr Soc
Huvudupphovsmän: Sølling, Anne Sophie K, Harsløf, Torben, Langdahl, Bente Lomholt
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Bone and Mineral Metabolism
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207527/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1217
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk